Clinical Trial Update: A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing Zidesamtinib (NVL-520) in patients with ROS1-rearranged non-small cell lung cancer and other ROS1-rearranged solid tumors; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ros1-rearranged Solid Tumors

Drugs mentioned

• Zidesamtinib (NVL-520) (Zidesamtinib)

Snippet

Sponsor: Nuvalent Inc. | Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING